[6-K] Galmed Pharmaceuticals Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. filed a Form 6-K to furnish a press release announcing top-line results from oncology mechanism-of-action studies. The research examined a three-drug combination of Aramchol, Stivarga and Metformin in gastrointestinal (GI) tumor cells. According to the press release title, this combination significantly enhanced GI tumor cell killing in both in-vivo and in-vitro models. The 6-K mainly serves to formally provide this press release to the market as an exhibit for investors and regulators.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of November 2025

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On November 17, 2025, Galmed Pharmaceuticals Ltd. issued a press release entitled “Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga^® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro.”

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release, dated November 17, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: November 17, 2025	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer

FAQ

What did Galmed Pharmaceuticals (GLMD) report in this Form 6-K?

Galmed Pharmaceuticals filed a Form 6-K to provide a press release announcing top-line results from oncology mechanism-of-action studies using a three-drug combination targeting GI tumor cells.

What is the focus of Galmed Pharmaceuticals' new oncology study results?

The study highlighted in the Form 6-K focuses on a three-drug combination of Aramchol, Stivarga and Metformin and its effect on gastrointestinal tumor cells.

How does Galmed describe the impact of the drug combination on GI tumor cells?

In the press release title, Galmed states that the three-drug combination significantly enhanced GI tumor cells killing in both in-vivo and in-vitro settings.

When was the Galmed Pharmaceuticals oncology press release issued?

The press release titled “Galmed Announces Top-line Results in Oncology MoA Studies” was issued on November 17, 2025.

What exhibit is attached to Galmed Pharmaceuticals' November 2025 Form 6-K?

The filing includes Exhibit 99.1, which is the full press release dated November 17, 2025 describing the top-line oncology study results.

Who signed the November 2025 Galmed Pharmaceuticals Form 6-K?

The Form 6-K was signed on behalf of Galmed Pharmaceuticals Ltd. by Allen Baharaff, its President and Chief Executive Officer.